Eczema, gene therapies, antimicrobial glass

labiotech | April 19, 2019

Try as we might, we can’t cover all the fascinating biotech news that is out there. Here’s a roundup of what didn’t make the cut over the last couple of weeks. Clinical trials UK biotech SkinBio Therapeutics reported that its candidate ‘microbiome’ cream for treating eczema is safe and helps improve skin hydration in a first test in healthy volunteers. Adocia announced positive early results from a phase I trial of a new formulation of pramlintide and fast-acting insulin developed by the French company for treatment of type 1 diabetes. 72-week results from GenSight Biologics phase III trial of its gene therapy for Leber Hereditary Optic Neuropathy showed continued sight improvement in patients, but no notable difference in improvement between placebo and gene-therapy treated eyes. Regulations and funding Dutch biotech Uniqure received US FDA fast track status for its gene therapy for treating Huntington’s disease, which should allow the treatment to be approved more quickly if found to be effective. The US FDA approved UK-based ViiV Healthcare’s Dovato, a once-daily, single-tablet, two-drug regimen for previously untreated adults with HIV infection. Nanna Therapeutics, a UK biotech developing drugs to target age-related  iseases, received a grant of €960,291 from Innovate UK to help develop its drugs targeting mitochondrial disorders and related conditions. UK-based Arterius and researchers at the University of Bristol received a €1.3M grant from Innovate UK to fund a collaboration to develop biodegradable stents for implantation in patients with serious cardiovascular disease. Irish biotech Avectas raised €8.9M in equity funding to develop its non-viral cell engineering technology for use in cell and gene therapies. Probiodrug, a German biotech, raised €8.2M from private sales of shares to help fund a phase IIb trial of its Alzheimer’s therapy and to develop new immune checkpoint inhibitors to target cancer. International molecular diagnostics firm Yourgene Health says it’s planning to buy UK-based genetic testing company Elucigene for a proposed €10.6M to expand its genetic test portfolio.

Spotlight

Establishing the safety of food and feed produced from biotechnology-derived crop products that contain a single trait relies mainly on the comparative safety assessment process. This comparative safety assessment process focuses on the assessment of any differences between the GM crop (and/or food and feed) and its conventional counterpart; and includes detailed molecular, compositional, phenotypic, and agronomic analyses.

Spotlight

Establishing the safety of food and feed produced from biotechnology-derived crop products that contain a single trait relies mainly on the comparative safety assessment process. This comparative safety assessment process focuses on the assessment of any differences between the GM crop (and/or food and feed) and its conventional counterpart; and includes detailed molecular, compositional, phenotypic, and agronomic analyses.

Related News

AI

eureKARE and DNAlytics Form Partnership to Develop a Proprietary AI Platform

eureKARE | July 07, 2021

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with new science and then attempt to find an issue to address with it, eureKARE's methodology reverses this. eureKARE is committed to first finding an unmet need and then enlisting the best scientists and experts to provide an innovative solution to launch exciting new ventures. This process will be aided by eureKARE's one-of-a-kind AI platform, which will assist the business in identifying top academic researchers, locating new ideas and approaches in development, and scaling existing portfolio companies. About eureKARE eureKARE is a ground-breaking new company focusing on financing and establishing next-generation biotechnology start-ups in the microbiome and synthetic biology cutting-edge areas. eureKARE employs a two-step investing strategy to create long-term value. Through its biotech start-upstart-up studios eureKABIOME (Microbiome) and eureKASYNBIO, the company promotes translational research by developing and financing new companies based on high-value European science (Synthetic biology). In addition, the company aims to engage in more mature biotech companies. It will systematically propose to provide some liquidity to early investors, thus fulfilling a crucial demand in the European biotech sector. EureKARE has a fast-expanding portfolio of companies with the potential to disrupt the life sciences sector, led by its prominent founder, Alexandre Mouradian, and a pan-European team. About DNAlytics DNAlytics is based in Louvain-la-Neuve, Belgium, specializing in data science for the healthcare sector, including data management, bioinformatics, biostatistics, Machine Learning, and other Artificial Intelligence methods. DNAlytics products are utilized in clinical research, the creation of biotech drugs and medical devices, public health studies, and the monitoring and optimization of bio-manufacturing processes. In addition, DNAlytics assists a wide range of clients and partners in extracting scientifically sound observations and practical conclusions from complex data sets.

Read More

MEDICAL

GenScript Launches GMP Single-Strand and Double-Strand DNA Service for Supporting Gene and Cell Therapy Development

GenScript | May 18, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services. These services will enable next-generation gene and cell therapy R&D programs to advance to IND filing and clinical trials faster and more efficiently. Today's announcement, made at the American Society of Gene & Cell Therapy (ASGCT) 25th annual meeting (booth #280), further establishes GenScript as the leading provider of non-viral homology-directed repair (HDR) template solutions for immune-cell engineering. GenScript now offers varying grades of non-viral HDR payload materials that support use cases across early discovery research, process development, and clinical studies. CRISPR-based non-viral gene insertion methods have gained popularity among research teams with concerns about the FDA's recent draft guidance concerning the use of viruses for gene and cell therapy. Non-viral HDR templates, in combination with CRISPR technology, can accelerate cell engineering compared to traditional GMP virus-based engineering, delivering results faster than alternate techniques. This new investment by GenScript demonstrates our commitment to non-viral delivery technology. We look forward to continuing to work with our partners and stakeholders in academia and industry to support their cell therapy R&D programs and further development of non-viral delivery platforms and workflows, We know this technology will be a more efficient and safer solution for cell engineering." Ray Chen, PhD, president of GenScript USA Life Science Group. GenScript's GMP ssDNA And dsDNA services enable faster CAR-T drug development: GenExact™ ssDNA up to 5000nt in length, 100mg/batch production scale GenWand™ closed-end, linear dsDNA up to 10,000nt in length, gram level/batch production scale GenScript has been collaborating with several academic and industry partners in the development of CRISPR non-viral gene insertion. Recently, Dr. Alex Marson's lab at UCSF published a paper demonstrating how CRISPR RNP technology can both knock out endogenous T-cell receptors and integrate replacement anti-cancer receptors. The UCSF team has been using GenScript's latest single-strand DNA to improve non-viral gene knock-in efficiency. Working in collaboration with GenScript, the team engineered modifications to the DNA payload to promote co-localization and delivery (or 'shuttle') to the nucleus. About GenScript Biotech Corporation GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. GenScript was founded in New Jersey, USA in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the USA, mainland China, Hong Kong, Japan, Singapore, the Netherlands, and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

Read More

Moleculin Announces Discovery of Significant In Vitro Activity Against SARS-CoV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repeatedly demonstrated a therapeutic index of greater than 10, which is considered by our team to be an industry-standard commercialization threshold for in vitro performance of antiviral drugs. Walter Klemp, Chairman and CEO of Moleculin, stated, "While we continue to see encouraging progress with WP1122 in preparation for clinical trials for the potential treatment of COVID-19, we have also continued our antiviral drug discovery program to expand the range of potential therapies. Our efforts led to a new discovery that we believe can be a game-changer. WP1096 and its close analog, WP1097, are structurally slightly different agents within the WP1122 portfolio. However, small structural changes unexpectedly resulted in high levels of antiviral activity and potentially a unique mode of action.

Read More